Vaccine Therapy Disappoints for Kidney Cancer

Courtesy MedPage Today Infectious Disease  Thu, 07/03/2008 - 17:30

HOUSTON -- The tumor-derived vaccine vitespen (Oncophage) does not prevent kidney cancer recurrence or improve survival despite promising early results, researchers said.

Sponsors

 

Related items

Plasma DNA level is a reliable marker of recurrent esophageal ca...
(Weber Shandwick Worldwide) New research published in the July issue of the Journal of the American College of Surgeons shows elevated plasma DNA is...

Weizmann Institute scientists' new technique gets to the root of...
(Weizmann Institute of Science) In two complementary studies, Weizmann Institute scientists have developed a new method for reconstructing a cell's...

Stanford researchers find molecule that kills kidney cancer cell...
(Stanford University Medical Center) Kidney cancer patients generally have one option for beating their disease: surgery to remove the organ. But...

Patient Web sites used for news, support in crisis
NEW YORK -- When he was diagnosed with kidney cancer last year, Dave deBronkart needed an easy way to keep his far-flung friends and family updated....

Patient Web sites used for news, support in crisis
NEW YORK (AP) -- When he was diagnosed with kidney cancer last year, Dave deBronkart needed an easy way to keep his far-flung friends and family...


 

Post new comment

The content of this field is kept private and will not be shown publicly.
health-fitness.marc8.com